Abstract
Lymphatic leukemia L 1210 cells were treated in vitro with various concentrations of Mafosfamide — a stabilized active derivative of cyclophosphamide (4-hydroxycyclophosphamide). L 1210 cells treated with Mafosfamide (L 1210-MAF cells) were used for vaccination of semisyngeneic CD2F1 mice against L 1210 leukemia. These cells do not grow in vivo but are viable in the test with trypan blue. L 1210-MAF cells, obtained by treatment of L 1210 cells two times with 50 μg/ml or 100 μg/ml of Mafosfamide, and injected into the mice induced resistance against L 1210 leukemia in these animals. L 1210 cells treated two times with higher concentration of Mafosfamide (200 μg/ml or 400 μg/ml) did not give this effect.
Similar content being viewed by others
References
Alberts DS, Einspahr JG, Struck R, Bignami G, Young L, Surwit EA, Salmon SE: Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Invest New Drugs 2:141–148, 1984
Turk JL, Parker D: Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 65:99–113, 1982
Diamantatein T, Klos M, Hahn H, Kaufmann SHE: Direct in vitro evidence for different susceptibilities to 4-hydroxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: a possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses. J Immunol 126:1717–1719, 1981
Douay L, Corin NC, Laporte J-P, Lopez M, Najman A, Duhamel G: ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs 2:187–190, 1984
Kawalec M, Jakóbisiak M, Skórski T, Kawiak J: Immunogenicity of cyclophosphamide-treated leukemia cells. Folia Biol (Praha) 28:334–343, 1982
Skórski T, Kawalec M, Hoser G: Cyclophosphamide or ifosfamide treated L 1210 leukemia cells: immunogenicity, viability and metabolism. Folia Biol (Praha) 32:354–365, 1986
Lichtfield JT: A method for rapid graphic solution of time-percent effect curves. J Pharmacol Exp Ther 97:399–408, 1949
Lichtfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113, 1949
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skórski, T., Kawalec, M. New application of a stabilized active cyclophosphamide derivative (Mafosfamide, ASTA Z 7654) — immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug. Invest New Drugs 5, 167–169 (1987). https://doi.org/10.1007/BF00203542
Issue Date:
DOI: https://doi.org/10.1007/BF00203542